113 related articles for article (PubMed ID: 24920845)
21. Real-time bioluminescence imaging of polycythemia vera development in mice.
Ma Y; Zhao S; Zhu J; Bettano KA; Qu X; Marshall CG; Young JR; Kohl NE; Scott ML; Zhang W; Wang Y
Biochim Biophys Acta; 2009 Nov; 1792(11):1073-9. PubMed ID: 19715759
[TBL] [Abstract][Full Text] [Related]
22. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; Mesa R; Li CY; Wadleigh M; Lee SJ; Gilliland DG
Cancer; 2006 Feb; 106(3):631-5. PubMed ID: 16369984
[TBL] [Abstract][Full Text] [Related]
23. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
24. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
25. Critical requirement for Stat5 in a mouse model of polycythemia vera.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
[TBL] [Abstract][Full Text] [Related]
26. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway.
De Grandis M; Cambot M; Wautier MP; Cassinat B; Chomienne C; Colin Y; Wautier JL; Le Van Kim C; El Nemer W
Blood; 2013 Jan; 121(4):658-65. PubMed ID: 23160466
[TBL] [Abstract][Full Text] [Related]
27. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
[TBL] [Abstract][Full Text] [Related]
28. The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera.
Falchi M; Varricchio L; Martelli F; Marra M; Picconi O; Tafuri A; Girelli G; Uversky VN; Migliaccio AR
Exp Hematol; 2017 Jun; 50():53-76. PubMed ID: 28232234
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of vorinostat in a murine model of polycythemia vera.
Akada H; Akada S; Gajra A; Bair A; Graziano S; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(16):3779-89. PubMed ID: 22408262
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
Pardanani A; Lasho TL; Finke C; Hanson CA; Tefferi A
Leukemia; 2007 Sep; 21(9):1960-3. PubMed ID: 17597810
[TBL] [Abstract][Full Text] [Related]
31. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
32. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
Grinfeld J; Godfrey AL
Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
[TBL] [Abstract][Full Text] [Related]
33. Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
Kraus M; Wang Y; Aleksandrowicz D; Bachman E; Szewczak AA; Walker D; Xu L; Bouthillette M; Childers KM; Dolinski B; Haidle AM; Kopinja J; Lee L; Lim J; Little KD; Ma Y; Mathur A; Mo JR; O'Hare E; Otte RD; Taoka BM; Wang W; Yin H; Zabierek AA; Zhang W; Zhao S; Zhu J; Young JR; Marshall CG
PLoS One; 2012; 7(5):e37207. PubMed ID: 22623993
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.
Gangat N; Strand J; Lasho TL; Finke CM; Knudson RA; Pardanani A; Li CY; Ketterling RP; Tefferi A
Eur J Haematol; 2008 Mar; 80(3):197-200. PubMed ID: 18081705
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera.
Abdel-Naser MB; Zaki MS; Mousa MH; Hamed H; Rizk MS; Mohamed HE; Habib MA
J Cutan Pathol; 2007 Dec; 34(12):924-9. PubMed ID: 18001415
[TBL] [Abstract][Full Text] [Related]
36. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
37. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
[TBL] [Abstract][Full Text] [Related]
38. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
[TBL] [Abstract][Full Text] [Related]
39. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
